Navigation Links
FDA: Majority of Drug and Biological Product Makers Meeting Postmarketing Requirements and Commitments
Date:11/9/2010

SILVER SPRING, Md., Nov. 9, 2010 /PRNewswire-USNewswire/ -- Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The study, based on the second annual review of the status of 1,551 postmarketing studies/clinical trials, showed that 40 percent of the postmarketing studies/clinical trials had been closed (either fulfilled or released) by FDA. Of the remaining 60 percent, most were in progress and on schedule or the final report has been submitted for FDA review.

The review, done under a contract with Booz Allen Hamilton, examined the backlog of industry postmarketing studies and clinical trials for FDA-approved drugs and biologics. The backlog was defined as all those postmarketing requirements (PMR) and postmarketing commitments (PMC) open when the Food and Drug Administration Amendments Act (FDAAA) was enacted on Sept. 27, 2007.

Under the FDAAA, the agency must annually report the status of the backlog of PMR and PMC for all approved drug and biological products. In addition, manufacturers of drugs and biologics are required to report to the FDA in a timely manner any serious safety issues that are identified from studies or other sources.

Key findings of the study include:

  • During the second annual review, the status of 591 PMR/PMCs changed. Nearly half (46 percent) of the PMR/PMCs were updated to fulfilled status, which reflects a significant effort by FDA staff to complete reviews of the large number of submitted final reports identified during the first annual review. Those remaining were updated as a result of study/trial initiation and completion, final report submission or missed milestone dates;
  • Only 17 percent of the backlog of PMRs/PMCs were delayed;
  • Just 7 percent of PMRs/PMCs on schedule after the first annual review became delayed during the second review.

For more information:

FR Notice – Final Report on the Postmarketing Requirement/Postmarketing Commitment Backlog Review (URL not live yet) http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/ucm064436.htm

09/04/09 – Final Report on the Postmarketing Requirement/Postmarketing Commitment Backlog Review

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/ucm180982.htm

#

Visit the FDA on Facebook and Flickr

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
2. RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs
3. Nycomed to Accelerate Expansion in China Through Acquisition of Majority Stake in Guangdong Techpool Bio-Pharma
4. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
5. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
6. Survey Reveals Majority of Americans Hold onto Myths About What Causes Colds and How to Treat Them
7. Martek Biosciences Announces Agreement to Sell Majority of Winchester, Ky. Manufacturing Site
8. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
9. Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
10. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
11. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... for PET Imaging in Top 5 EU Markets"  report to ... This report provides information on the current Positron Emission ... Five European Markets (T5 EU), which includes France ... , Spain and the ...
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
(Date:5/4/2016)... -- Yissum Research Development Company of ... it had signed an exclusive world-wide licensing and research ... protein degradation and immunomodulatory drugs for cancer and immune ... representing first-in-class therapy for hematologic and solid malignancies. Financial ... The novel technology was developed by Yinon Ben-Neriah ...
Breaking Medicine Technology:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... From May ... Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s technology ... independent practice growth. , “It is our priority to see practices succeed in this ...
(Date:5/6/2016)... San Diego, CA (PRWEB) , ... May 06, 2016 , ... ... of Companies, has been family-owned and operated for over 35 years. Maintaining core values ... community has driven their success and made them a leading name in San Diego ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... and David Konur, CEO of Cardiovascular Institute of the South announced today that ... performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
(Date:5/5/2016)... ... May 05, 2016 , ... Florida Hospital Pepin ... atrial fibrillation (A-Fib) an alternative to long-term warfarin medication with the newly approved ... April of 2015, Florida Hospital Pepin Heart Institute doctors successfully implanted the Watchman ...
Breaking Medicine News(10 mins):